1 |
34265801 |
10.1097/PAS.0000000000001780 |
2022 |
Plasticity of Mature B Cells Between Follicular and Classic Hodgkin Lymphomas: A Series of 22 Cases Expanding the Spectrum of Transdifferentiation. |
XPO1 |
2 |
36001451 |
10.1097/PAS.0000000000001956 |
2022 |
Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas. |
XPO1 |
3 |
32079702 |
10.3324/haematol.2019.237719 |
2021 |
Targeted genotyping of circulating tumor DNA for classical Hodgkin lymphoma monitoring: a prospective study. |
XPO1 |
4 |
32961552 |
10.1182/blood.2020007507 |
2021 |
Mutational landscape of gray zone lymphoma. |
XPO1 |
5 |
33263441 |
10.1080/17474086.2021.1856652 |
2021 |
Development of molecular intervention strategies for B-cell lymphoma. |
XPO1 |
6 |
33959502 |
10.3389/fonc.2021.638897 |
2021 |
c-Rel Is the Pivotal NF-κB Subunit in Germinal Center Diffuse Large B-Cell Lymphoma: A LYSA Study. |
XPO1 |
7 |
34405005 |
10.7150/jca.60390 |
2021 |
Serial surveillance by circulating tumor DNA profiling after chimeric antigen receptor T therapy for the guidance of r/r diffuse large B cell lymphoma precise treatment. |
XPO1 |
8 |
31789821 |
10.1097/PAI.0000000000000820 |
2020 |
EBV-Positive Primary Large B-Cell Lymphoma: The Role of Immunohistochemistry and XPO1 in the Diagnosis of Mediastinal Lymphomas. |
XPO1 |
9 |
31822802 |
10.1038/s41379-019-0428-0 |
2020 |
Diagnostic utility of STAT6<sup>YE361</sup> expression in classical Hodgkin lymphoma and related entities. |
XPO1 |
10 |
32045477 |
10.1182/bloodadvances.2019000359 |
2020 |
Venetoclax response is enhanced by selective inhibitor of nuclear export compounds in hematologic malignancies. |
XPO1 |
11 |
32565964 |
10.3892/ol.2020.11552 |
2020 |
Comprehensive characterization of driver genes in diffuse large B cell lymphoma. |
XPO1 |
12 |
32691208 |
10.1007/s11060-020-03580-y |
2020 |
Repolarization of tumor infiltrating macrophages and increased survival in mouse primary CNS lymphomas after XPO1 and BTK inhibition. |
XPO1 |
13 |
33154951 |
10.3389/fonc.2020.591577 |
2020 |
Genetic and Non-Genetic Mechanisms of Resistance to BCR Signaling Inhibitors in B Cell Malignancies. |
XPO1 |
14 |
33202794 |
10.3390/ijms21228553 |
2020 |
Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma. |
XPO1 |
15 |
30108156 |
10.1634/theoncologist.2018-0058 |
2019 |
Comprehensive Genomic Profiling of Hodgkin Lymphoma Reveals Recurrently Mutated Genes and Increased Mutation Burden. |
XPO1 |
16 |
30211726 |
10.1097/PAS.0000000000001154 |
2019 |
Cyclin D1-positive Mediastinal Large B-Cell Lymphoma With Copy Number Gains of CCND1 Gene: A Study of 3 Cases With Nonmediastinal Disease. |
XPO1 |
17 |
31296529 |
10.1158/1078-0432.CCR-19-0273 |
2019 |
Eμ-TCL1xMyc: A Novel Mouse Model for Concurrent CLL and B-Cell Lymphoma. |
XPO1 |
18 |
31752970 |
10.1186/s13045-019-0803-9 |
2019 |
Simultaneous targeting of XPO1 and BCL2 as an effective treatment strategy for double-hit lymphoma. |
XPO1 |
19 |
31816062 |
10.1182/bloodadvances.2019001012 |
2019 |
Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. |
XPO1 |
20 |
29650799 |
10.1182/blood-2017-11-814913 |
2018 |
Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma. |
XPO1 |
21 |
29989027 |
10.18632/oncotarget.25601 |
2018 |
New generation sequencing of targeted genes in the classical and the variant form of hairy cell leukemia highlights mutations in epigenetic regulation genes. |
XPO1 |
22 |
30510142 |
10.1158/1535-7163.MCT-17-0789-ATR |
2018 |
XPO1 Inhibitor Selinexor Overcomes Intrinsic Ibrutinib Resistance in Mantle Cell Lymphoma via Nuclear Retention of IκB. |
XPO1 |
23 |
26608593 |
10.1002/gcc.22328 |
2016 |
Whole exome sequencing of relapsed/refractory patients expands the repertoire of somatic mutations in diffuse large B-cell lymphoma. |
XPO1 |
24 |
26819451 |
10.1158/1078-0432.CCR-15-2305 |
2016 |
Next-Generation Sequencing in Diffuse Large B-Cell Lymphoma Highlights Molecular Divergence and Therapeutic Opportunities: a LYSA Study. |
XPO1 |
25 |
26883583 |
10.3109/10428194.2016.1139703 |
2016 |
Digital PCR for quantification of recurrent and potentially actionable somatic mutations in circulating free DNA from patients with diffuse large B-cell lymphoma. |
XPO1 |